Prof. Dr. med. H Christian Reinhardt - Curriculum Vitae

Education and professional career

2017: Speaker of the Kröner Forschungskolleg "Clonal Evolution in Cancer"
2015: Attending physician (Oberarzt), Department of Internal Medicine I
2015: Board exam, certified in general internal medicine, hematology / oncology
2015: Member of the executive board, Center for Molecular Medicine Cologne
since 2013: Head of the Clinical Research Unit 286 ‘Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia’
since 2012: Elected member of the steering committee of the Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC) and scientific coordinator of Research Topic 3, Hematological Malignancies within the PCCC
since 2012: Scientific coordinator of Research Area C (DNA damage response) within the Excellence Cluster CECAD
since 2012: Professor for Clinical and Molecular Oncology, University of Cologne
2010: Certified Clinical Research Physician
since 2009: Emmy-Noether research group leader, Max-Planck-Institute Cologne and Department of Internal Medicine I, University of Cologne
2008: ‘Habilitation’ Molecular Medicine, Medical Faculty, University of Cologne
2004 - 2009: Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD
2004: Postdoctoral Research Fellow, University of Münster, Advisor: Prof. Dr. H. Pavenstädt
2003:
Postdoctoral Research Fellow, University of Freiburg, Advisor: Prof. Dr. G. Walz and Dr. T. Benzing
1999 - 2003: MD thesis in Internal Medicine, University of Freiburg, grade: Summa cum laude
1996 - 2003: Medical school, University of Hamburg, Humboldt University Berlin, University of Freiburg, final grade: highest honors

Awards, distinctions and professional activities

2016: Theodor Frerichs Award of the German Society for Internal Medicine
2012:
GlaxoSmithKline Research Award
2011: Vincenz Czerny Award of the German Society for Hematology and Oncology
2011: W2 Lichtenberg Professorship, VolkswagenStiftung
2011: CESAR Research Award of the Central European Society for Anticancer Drug Research
2011: Johann-Georg-Zimmermann Award for Cancer Research
2010: Young Leaders in Science Award, Schering Stiftung
2009: Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft
2009: Startup grant, Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia
2009: NIH / NCI K99 / R00 PI award (relinquished due to return to Germany)
2009: Travel grant of the Deutsche Krebshilfe
2007: MIT-Koch Award
2005: Research fellowship of the Deutsche Forschungsgemeinschaft
2004: Young investigator award of the Deutsche Nierenstiftung

Selected publications

Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 2007, Feb;11(2):175-89.
Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell. 2010, 40;1, 34-49, 2010, Oct 8.

Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell. 2008, Oct 17;135(2):343-54.*equal contribution.

Jiang H*, Reinhardt HC*, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT: The ATM-Chk2 Signaling Network Controls Alternative Cell Fates after Chemotherapy Based on a p53 Binary Switch. Genes Dev. 2009, Aug 15;23(16):1895-909. *equal contribution.

Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretic L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell. 2015, Jul 2; 1; 146-159.

Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, Published Online First. 2014, Feb 20.

Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med. 2013, Jun 12;5(189):189ra78. doi: 10.1126/scitranslmed.3005814.

Höpker K, Hagmann H, Khurshid S, Chen S, Hasskamp P, Seeger-Nukpezah T, Schilberg K, Heukamp L, Lamkemeyer T, Sos M, Thomas R, Lowery D, Fischer M, Roels F, Liebau MC, Resch U, Kisner T, Röther F, Bartram MP, Müller RU, Fabretti F, Kurschat P, Schumacher B, Medema R, Yaffe MB,
Schermer B, Reinhardt HC*, Benzing T*: AATF/Che1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO J. 2012, Oct 17;31(20):3961-75. *equal contribution.

George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature. 2015, Jul 13. doi: 10.1038/nature14664. [Epub ahead of print].

Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB.: 14-3-3sigmacontrols mitotic translation to facilitate cytokinesis. Nature. 2007, Mar 15;446(7133).